| pubmed-article:11123978 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11123978 | lifeskim:mentions | umls-concept:C0598245 | lld:lifeskim |
| pubmed-article:11123978 | lifeskim:mentions | umls-concept:C0070319 | lld:lifeskim |
| pubmed-article:11123978 | lifeskim:mentions | umls-concept:C0450442 | lld:lifeskim |
| pubmed-article:11123978 | lifeskim:mentions | umls-concept:C0053294 | lld:lifeskim |
| pubmed-article:11123978 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:11123978 | pubmed:dateCreated | 2001-1-22 | lld:pubmed |
| pubmed-article:11123978 | pubmed:abstractText | A series of arylalkyl isothiocyanates were evaluated for their ability to inactivate purified cytochrome P450 2B1 in a reconstituted system. Benzyl isothiocyanate (BITC) and phenethyl isothiocyanate (PEITC) occur naturally in several cruciferous vegetables, and the inhibition of cytochrome P450 (P450) enzymes has been implicated in their chemopreventative abilities. The naturally occurring isothiocyanates BITC and PEITC inactivated P450 2B1 in a time- and concentration-dependent manner, whereas the synthetic isothiocyanates phenylpropyl and phenylhexyl isothiocyanate did not result in inactivation, but were potent competitive inhibitors of P450 2B1 activity. The kinetics of inactivation of P450 2B1 by BITC were characterized. The 7-ethoxy-4-(trifluoromethyl)coumarin O-deethylation activity of P450 2B1 was inactivated in a mechanism-based manner. The loss of O-deethylation activity followed pseudo-first-order kinetics, was saturable, and required NADPH. The BITC concentration required for half-maximal inactivation (K(I)) was 5.8 microM, and the maximal rate constant for inactivation was 0.66 min(-)(1) at 23 degrees C. BITC was a very efficient inactivator of P450 2B1 with a partition ratio of approximately 9. The mechanism of BITC-mediated inactivation of P450 2B1 was also investigated. More than 80% of the catalytic activity was lost within 12 min with a concomitant loss of approximately 45% in the ability of the reduced enzyme to bind CO. The magnitude of the UV/visible absorption spectrum of the inactivated protein did not decrease significantly, and subsequent HPLC analysis indicated no apparent modification of the heme. HPLC and protein precipitation analyses indicated that the P450 apoprotein was covalently modified by a metabolite of BITC. Determination of the binding stoichiometry indicated that 0.90 +/- 0. 16 mol of radiolabeled metabolite was bound per mole of enzyme that was inactivated, suggesting the modification of a single amino acid residue per molecule of enzyme that was inactivated. The results reported here indicate that BITC is a mechanism-based inactivator of P450 2B1 and that inactivation occurs primarily through protein modification. | lld:pubmed |
| pubmed-article:11123978 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11123978 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11123978 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11123978 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11123978 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11123978 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11123978 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11123978 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11123978 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11123978 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11123978 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11123978 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11123978 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:11123978 | pubmed:issn | 0893-228X | lld:pubmed |
| pubmed-article:11123978 | pubmed:author | pubmed-author:BrandLL | lld:pubmed |
| pubmed-article:11123978 | pubmed:author | pubmed-author:HollenbergP... | lld:pubmed |
| pubmed-article:11123978 | pubmed:author | pubmed-author:KentU MUM | lld:pubmed |
| pubmed-article:11123978 | pubmed:author | pubmed-author:GoosenT CTC | lld:pubmed |
| pubmed-article:11123978 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11123978 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:11123978 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11123978 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11123978 | pubmed:pagination | 1349-59 | lld:pubmed |
| pubmed-article:11123978 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:11123978 | pubmed:meshHeading | pubmed-meshheading:11123978... | lld:pubmed |
| pubmed-article:11123978 | pubmed:meshHeading | pubmed-meshheading:11123978... | lld:pubmed |
| pubmed-article:11123978 | pubmed:meshHeading | pubmed-meshheading:11123978... | lld:pubmed |
| pubmed-article:11123978 | pubmed:meshHeading | pubmed-meshheading:11123978... | lld:pubmed |
| pubmed-article:11123978 | pubmed:meshHeading | pubmed-meshheading:11123978... | lld:pubmed |
| pubmed-article:11123978 | pubmed:meshHeading | pubmed-meshheading:11123978... | lld:pubmed |
| pubmed-article:11123978 | pubmed:meshHeading | pubmed-meshheading:11123978... | lld:pubmed |
| pubmed-article:11123978 | pubmed:meshHeading | pubmed-meshheading:11123978... | lld:pubmed |
| pubmed-article:11123978 | pubmed:meshHeading | pubmed-meshheading:11123978... | lld:pubmed |
| pubmed-article:11123978 | pubmed:meshHeading | pubmed-meshheading:11123978... | lld:pubmed |
| pubmed-article:11123978 | pubmed:meshHeading | pubmed-meshheading:11123978... | lld:pubmed |
| pubmed-article:11123978 | pubmed:meshHeading | pubmed-meshheading:11123978... | lld:pubmed |
| pubmed-article:11123978 | pubmed:meshHeading | pubmed-meshheading:11123978... | lld:pubmed |
| pubmed-article:11123978 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:11123978 | pubmed:articleTitle | Inactivation of cytochrome P450 2B1 by benzyl isothiocyanate, a chemopreventative agent from cruciferous vegetables. | lld:pubmed |
| pubmed-article:11123978 | pubmed:affiliation | Department of Pharmacology, Potchefstroom University for Christian Higher Education, Potchefstroom 2520, South Africa. | lld:pubmed |
| pubmed-article:11123978 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11123978 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:11123978 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:11123978 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11123978 | lld:pubmed |
